Bio-Techne Corporation has acquired Cliniqa Corporation to enhance its clinical diagnostics product portfolio and expand its market presence.

Target Company Overview

Bio-Techne Corporation has successfully acquired 100% of Cliniqa Corporation, a company renowned for its manufacturing and commercialization of quality controls, calibrators, and bulk reagents tailored for the clinical diagnostics market. Cliniqa’s extensive portfolio plays a critical role in ensuring the precision of diagnostic testing, thereby enhancing the dependability of patient outcomes in healthcare.

The management team at Cliniqa is distinguished by its formidable expertise in clinical diagnostics and regulatory affairs, boasting over 165 510(k) clearances from the U.S. Food and Drug Administration. This extensive experience positions Cliniqa as a valuable asset to Bio-Techne, further consolidating its commitment to delivering innovative diagnostic solutions.

Industry Overview in the United States

The clinical diagnostics industry in the United States is experiencing a robust transformation characterized by technological advancements and an increasing de